)
)
LENZ Therapeutics Investor Relations Material
Latest events
Q3 2024
LENZ Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from LENZ Therapeutics Inc
Access all reports
LENZ Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on treating presbyopia, a common age-related condition that affects near vision. LENZ Therapeutics is currently advancing its lead product candidates, LNZ100 and LNZ101, which are in Phase III clinical trials. These products are aceclidine-based eye drops designed to restore near vision for individuals with presbyopia. The company is headquartered in Del Mar, California, and its shares are listed on the NASDAQ.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
LENZ
Country
🇺🇸 United States